Concepedia

Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins

Minh Tung Phung, Alice W. Lee, Anna H. Wu, Andrew Berchuck, Kathleen R. Cho, Daniel W. Cramer, Jennifer A. Doherty, Marc T. Goodman, Gillian E. Hanley, Holly R. Harris,

Cancer Epidemiology Biomarkers & Prevention · 2021 · 20 citations · 32 references

DOIFull text

Open access

Abstract

The results of this study are of particular interest given the rise in popularity of progestin-releasing intrauterine devices that have a substantially lower progestin dose than that in DMPA, but may have a stronger local effect.

References

32

Rayyan—a web and mobile app for systematic reviews

Mourad Ouzzani, Hossam M. Hammady, Zbys Fedorowicz et al. · Systematic Reviews · 2016 · 22.2K citations · Full text

The Reduction in Risk of Ovarian Cancer Associated with Oral-Contraceptive Use

New England Journal of Medicine · 1987 · 366 citations

Contraceptive Methods Women Have Ever Used: United States, 2015-2019

Kimberly Daniels · 2023 · 247 citations · Full text

Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer

Melissa A. Merritt, Adèle C. Green, Christina M. Nagle et al. · International Journal of Cancer · 2007 · 222 citations · Full text

Pharmacokinetics of depot medroxyprogesterone acetate contraception.

Daniel R. Mishell · PubMed · 1996 · 212 citations

, , +10